2018
Microenvironment Cell Contribution to Lymphoma Immunity
Kumar D, Xu ML. Microenvironment Cell Contribution to Lymphoma Immunity. Frontiers In Oncology 2018, 8: 288. PMID: 30101129, PMCID: PMC6073855, DOI: 10.3389/fonc.2018.00288.Peer-Reviewed Original ResearchLymphoma-associated macrophagesMesenchymal stem/stromal cellsT cellsLymphoma microenvironmentStromal cellsMarkers of exhaustionImmune checkpoint blockadeRegulatory T cellsEra of immunotherapyNatural killer cellsAnti-tumor effectsStem/stromal cellsLymphoma immunityTim-3Adverse eventsCheckpoint blockadeDendritic cellsImmune dysfunctionKiller cellsPD-1Immune cellsMechanisms of resistanceImmune escapeTumor surveillanceLAG-3
2015
Identification of a Cereblon-Independent Protein Degradation Pathway in Residual Myeloma Cells Treated with Immunomodulatory Drugs
Verma R, Mai Z, Xu M, Zhang L, Dhodapkar K, Dhodapkar M. Identification of a Cereblon-Independent Protein Degradation Pathway in Residual Myeloma Cells Treated with Immunomodulatory Drugs. Blood 2015, 126: 913. DOI: 10.1182/blood.v126.23.913.913.Peer-Reviewed Original ResearchResidual MM cellsDegradation of IKZF1MM cellsClonogenic growthRNAi-mediated inhibitionHDAC inhibitorsMyeloma cellsResidual myeloma cellsSynergistic anti-tumor effectImmune-modulatory drugsHuman MM cellsPrimary MM cellsAnti-myeloma effectTrichostatin AMM plasma cellsAnti-tumor effectsMM cell linesAnti-proliferative effectsConcurrent therapyImmunomodulatory drugsResidual diseaseModulatory drugsPlasma cellsT cellsRecent studies